These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 17196793)

  • 1. Dose-response population analysis of levetiracetam add-on treatment in refractory epileptic patients with partial onset seizures.
    Snoeck E; Stockis A
    Epilepsy Res; 2007 Mar; 73(3):284-91. PubMed ID: 17196793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures.
    Piña-Garza JE; Nordli DR; Rating D; Yang H; Schiemann-Delgado J; Duncan B;
    Epilepsia; 2009 May; 50(5):1141-9. PubMed ID: 19243423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study.
    Beran RG; Berkovic SF; Black AB; Danta G; Hiersemenzel R; Schapel GJ; Vajda FJ
    Epilepsy Res; 2005 Jan; 63(1):1-9. PubMed ID: 15716083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures.
    Wu XY; Hong Z; Wu X; Wu LW; Wang XF; Zhou D; Zhao ZX; Lv CZ
    Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pregabalin or placebo used adjunctively with levetiracetam in refractory partial-onset epilepsy: a post hoc efficacy and safety analysis in combined clinical trials.
    Uthman BM; Almas M; Emir B; Giordano S; Leon T
    Curr Med Res Opin; 2011 Jul; 27(7):1285-93. PubMed ID: 21561392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.
    Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM;
    Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study.
    Callenbach PM; Arts WF; ten Houten R; Augustijn P; Gunning WB; Peeters EA; Weber AM; Stroink H; Geerts Y; Geerts AT; Brouwer OF
    Eur J Paediatr Neurol; 2008 Jul; 12(4):321-7. PubMed ID: 17950011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures.
    Glauser TA; Ayala R; Elterman RD; Mitchell WG; Van Orman CB; Gauer LJ; Lu Z;
    Neurology; 2006 Jun; 66(11):1654-60. PubMed ID: 16641323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of levetiracetam in partial seizures.
    Devinsky O; Elger C
    Epileptic Disord; 2003 May; 5 Suppl 1():S27-31. PubMed ID: 12915338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate.
    Fountain NB; Conry JA; Rodríguez-Leyva I; Gutierrez-Moctezuma J; Salas E; Coupez R; Stockis A; Lu ZS
    Epilepsy Res; 2007 Apr; 74(1):60-9. PubMed ID: 17270398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levetiracetam extended release and levetiracetam immediate release as adjunctive treatment for partial-onset seizures: an indirect comparison of treatment-emergent adverse events using meta-analytic techniques.
    Richy FF; Banerjee S; Brabant Y; Helmers S
    Epilepsy Behav; 2009 Oct; 16(2):240-5. PubMed ID: 19699156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures.
    Zhou B; Zhang Q; Tian L; Xiao J; Stefan H; Zhou D
    Epilepsy Behav; 2008 Feb; 12(2):305-10. PubMed ID: 18024209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying baseline characteristics of placebo responders versus nonresponders in randomized double-blind trials of refractory partial-onset seizures.
    Niklson I; Edrich P; Verdru P
    Epileptic Disord; 2006 Mar; 8(1):37-44. PubMed ID: 16567324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial.
    Levisohn PM; Mintz M; Hunter SJ; Yang H; Jones J;
    Epilepsia; 2009 Nov; 50(11):2377-89. PubMed ID: 19702752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Onset of action of levetiracetam: a RCT trial using therapeutic intensive seizure analysis (TISA).
    Stefan H; Wang-Tilz Y; Pauli E; Dennhöfer S; Genow A; Kerling F; Lorber B; Fraunberger B; Halboni P; Koebnick C; Gefeller O; Tilz C
    Epilepsia; 2006 Mar; 47(3):516-22. PubMed ID: 16529615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials.
    Gidal BE; Baltès E; Otoul C; Perucca E
    Epilepsy Res; 2005; 64(1-2):1-11. PubMed ID: 15823510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy.
    Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I
    Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of seizure freedom in adjunctive therapy studies in refractory partial epilepsy: the levetiracetam experience.
    Leppik I; De Rue K; Edrich P; Perucca E
    Epileptic Disord; 2006 Jun; 8(2):118-30. PubMed ID: 16793573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjunctive levetiracetam in patients aged 1 month to <4 years with partial-onset seizures: subpopulation analysis of a prospective, open-label extension study of up to 48 weeks.
    Piña-Garza JE; Schiemann-Delgado J; Yang H; Duncan B; Hadac J; Hunter SJ
    Clin Ther; 2010 Oct; 32(11):1935-50. PubMed ID: 21095488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levetiracetam: new preparation. For some patients with refractory partial epilepsy.
    Prescrire Int; 2003 Apr; 12(64):53-4. PubMed ID: 12674114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.